The biology of CML blast crisis

Blood

Volumn 103, Issue 11, 2004, Pages 4010-4022

  Calabretta, Bruno ^a   Perrotti, Danilo ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN;

BLAST CELL CRISIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DISEASE COURSE; EVIDENCE BASED MEDICINE; GENE ACTIVITY; GENE CONTROL; GENETIC DISORDER; HUMAN; IN VITRO STUDY; MOLECULAR BIOLOGY; MYELOBLAST; NONHUMAN; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; STEM CELL; VALIDATION PROCESS;

EID: 2542500611     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4111     Document Type: Review

References (171)

1. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral center over a 16-year period. Br J Haematol. 1997;96:111-116.
2. Spiers AS. The clinical features of chronic granulocytic leukemia. Clin Hematol. 1977;6:77-95.
3. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445-454.
4. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497-1499.
5. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
6. Shtivelman E, Lifshitz B, Gale RB, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human cell gene and from the bcr/abl fused gene. Cell. 1986;47:272-284.
7. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene. Science. 1986;233:212-216.
8. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375-2384.
9. Mclaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the p210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A. 1987;84:6558-6562.
10. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 bcr/abl protein. Proc Natl Acad Sci U S A. 1988;85:9312-9316.
11. bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
12. Elefanty AG, Hariharan IK, Cory S. Bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9:1069-1078.
13. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WTV, Groffen J, Heisterkamp N. BCR/ABL p210 and p190 cause distinct leukemia in transgenic mice. Blood. 1995;86:4603-4611.
14. Weisdorf DJ, Anasetti C, Antin JH, at al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971-1977.
15. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-close cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
16. Kantarjian HM, Cortes JE, O'Brien SG, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.
17. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;343:1423-1432.
18. Gaiger A, Henn T, Horth E, et al. Increase of bcr/abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia proceeds disease progression. Blood. 1995;86:2371-2378.
19. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW. The amount of BCR/ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stages. Ann Hematol. 2000;79:424-431.
20. Jamieson CHM, Jones C, Zehnder J, Gotlib J, Manz M, Weissman IL. BCR/ABL expression by highly purified chronic myelogenous leukemia hematopoietic stem cells and myeloid progenitors pre- and post-imatinib therapy [abstract]. Blood. 2003;101:418a.
21. Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol. 1985;5:3116-3123.
22. McWhirter JR, Wang JY. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol. 1991;13:1553-1563.
23. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of the bcr-abl oncogene products. Science. 1990;247:1079-1082.
24. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR/ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541.
25. bcr/abl. Blood. 1992;80:1788-1797.
26. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR/ABL oncogene. Cell. 1995;82:981-988.
27. Sattler M, Mohi MG, Pride YB, et al. Critical role of Gab2 in transformation by BCR/ABL. Cancer Cell. 2002;1:479-492.
28. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the BCR/ABL oncogene. J Exp Med. 1995;181:307-313.
29. bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med. 1994;179:1855-1865.
30. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.
31. Varticovski L, Daley GA, Jackson P, Baltimore D, Cantley LC. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol. 1991;11:1107-1113.
32. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726-736.
33. BCR/ABL. Blood. 1996;88:1542-1550.
34. Jain SK, Langdon WY, Varticovski L. Tyrosine phosphorylation of p120 che in BCR/ABL transformed hematopoietic cells mediates enhanced association with phosphatidylinositol-3 kinase. Oncogene. 1997;14:2217-2228.
35. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway. EMBO J. 1997;16:6151-6161.
36. Vivanco I, Sawyers CL. The phosphatidylinositol-3 kinase/Akt pathway in human cancer. Nat Rev Cancer. 2002;2:489-501.
37. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;96:857-868.
38. Salomoni P, Condorelli F, Sweeney FM, Calabretta B. Versatility of BCR/ABL-expressing leukemic cells in circumventing pro-apoptotic BAD effects. Blood. 2000;96:676-684.
39. Mayo LD, Donner DB. A phosphatidylinositol-3 kinase/Akt pathway promotes translocation of MDM2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98:11598-11603.
40. Zhou BP, Liao Y, Xu W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001;3:973-982.
41. Ozes ON, Mayo LD, Justin JA, Pfeiffer SR, Pfeiffer RM, Donner DB. NF-kappaB activation by tumor necrosis factor requires the Akt-serine-threonine kinase. Nature, 1999;401:82-85.
42. Silverman N, Maniatis T. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001;15:2321-2342.
43. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-kappa B activation in BCR/ABL-mediated transformation, Genes Dev. 1998;12:968-981.
44. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868.
45. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and BCR/ABL mediate suppression of TRAIL-induced apoptosis through inhibition of Forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A. 2003;100:6523-6528.
46. Komatsu N, Watanebe T, Uchida M, et al. A member of the Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR/ABL-expressing cells. J Biol Chem. 2003;278:6411-6419.
47. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27 Kip1 through the phosphatidylinositol-3 kinase/Akt pathway. J Biol Chem. 2000; 275:39223-39230.
48. Parada Y, Banerji L, Glassford J, et al. BCR-ABL and interleukin 3 promote hematopoietic cell proliferation and survival through modulation of cyclin D2 and p27/Kip1 expression. J Biol Chem. 2001;276:23572-23580.
49. + cell proliferation: BCR/ABL upregulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to cell cytoplasm and incapable of regulating Cdk2 activity. Proc Natl Acad Sci U S A. 2000;47:10538-10543.
50. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27 (Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8:1136-1144.
51. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated GI arrest. Nat Med. 2002;8:1153-1160.
52. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8:1145-1152.
53. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR/ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247-254.
54. Ilaria RL, van Etten RA. p210 and p190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31704-31710.
55. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BCR/ABL. J Exp Med. 1996;183:811-820.
56. Frank DA, Varticovski L. BCR/ABL leads to the constitutive activation of STAT proteins and shares an epitope with tyrosine phosphorylated STAT. Leukemia. 1996;10:1724-1730.
57. Klajman A, Schreiner SJ, Nieborowska-Skorska M, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. 2002;21:5766-5774.
58. Nieborowska-Skorska M, Wasik MA, Slupianek KA, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 1999;189:1229-1242.
59. Horita M, Andrew EJ, Benito A, et al. Blockade of the BCR/ABL kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-XL. J Exp Med. 2000;191:977-984.
60. L by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev. 1998;12:2475-2487.
61. Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T. Complementary functions of the anti-apoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood. 2002;99:4531-4539.
62. Sexl V, Piekorz R, Moriggl R, et al. STAT5a/b contribute to interleukin7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of STAT5. Blood. 2000;96:2277-2283.
63. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR/ABL-expressing cell lines and peripheral blood cells derived from leukemia patients. J Immunol. 1997;159:4720-4728.
64. Huang M, Dorsey JF, Epling-Burnette PK, et al. Inhibition of BCR/ABL kinase activity by PD180970 blocks constitutive activation of STAT5 and growth of CML. Oncogene. 2002;21:8804-8816.
65. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR/ABL in chronic myeloid leukemia. Blood. 1994;83:2038-2044.
66. Eaves AC, Cashman JD, Gaboury LA, Krelomek DK, Eaves CJ. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci U S A. 1986;83:5306-5310.
67. Lapine J, Messner HA. Pluripotent hematopoietic progenitors (CFU-GEMM) in chronic myelogenous leukemia. Int J Cell Cloning. 1988;1:230-240.
68. Andreeff M. Cell kinetics of leukemia. Semin Hematol. 1986;23;300-314.
69. Strife A, Clarkson B. Biology of chronic myelogenous leukemia: is discordant maturation the primary defect? Semin Hematol. 1988;25:1-19.
70. Mayner-Satta V, Burl S, Liu L, et al. BCR/ABL accelerates C2-ceramide-induced apoptosis. Oncogene. 1998;16:237-248.
71. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96:12806-12809.
72. Clarkson B, Strife A, Wisniewski P, Lambeck CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible creative strategies. Leukemia 2003;17:1211-1262.
73. Deininger MW, Vieira SA, Parada Y, et al. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res. 2001;61:8005-8013.
74. Jena N, Deng M, Sicinska E, Sicinski P, Daley GQ. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res. 2002;62:535-541.
75. Jonuleit T, van der Kuip H, Miething C, et al. Bcr-Abl kinase downregulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood. 2000;96:1933-1939.
76. Cheng T, Rodrigues N, Shen H, et al. Hematopoietic stem cell prescience maintained by p21 cip1/waf1. Science. 2000;287:1804-1808.
77. kip1. Nat Med. 2000;6:1235-1240.
78. Holyoake TL, Jiang X, Drummond MW, Eaves AC, Eaves CJ. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia. 2002;16:544-558.
79. Shet AS, Jahagirder BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia. 2002;16:1402-1411.
80. cs. Blood. 2001;97:2084-2090.
81. Tuteja R, Tuteja N. Ku autoantigen: a multifunctional DNA-binding protein. Crit Rev Biochem Mol Biol. 2000;35:1-33.
82. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirements for DNA ends and association with Ku antigen. Cell. 1993;72:131-142.
83. Suwa A, Hirakata M, Takeda Y, Jesch SA, Mimod T, Hardin J. A DNA-dependent protein kinase (Ku protein-p350 complex) assembles on double-stranded DNA. Proc Natl Acad Sci U S A. 1994;91:6904-6908.
84. Ma Y, Pannicke U, Schwartz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in non-homologous end joining and V(D)J recombination. Cell. 2002;108:781-794.
85. McElhinny SAN, Snowden CM, McCarville J, Ramsden DA. Ku recruits the XRCC4-ligase IV complex to DNA ends. Mol Cell Biol. 2000;20:2996-3003.
86. Grawunder V, Wilm M, Wu X, et al. Activity of DNA ligase-IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature. 1997;388:492-495.
87. Wang H, Zeng ZC, Biu TA, et al. Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group. Oncogene. 2001;20:2212-2224.
88. Nacht M, Strasser A, Chan YR, et al. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev. 1996;10:2055-2066.
89. Sharpless NE, Ferguson DO, O'Hagan RC, et al. Impaired non-homologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol Cell. 2001;8:1187-1196.
90. Deutsch E, Jarrousse S, Buet D, et al. Downregulation of BRCA1 in BCR/ABL-expressing hematopoietic cells. Blood. 2003;101:4583-4588.
91. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol. 2003;15:345-350.
92. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene. 2002;21:8981-8983.
93. Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 2001;8:795-806.
94. Shinohara A, Ogawa T. Homologous recombination and the roles of double-strand breaks. Trends Biochem Sci. 1995;20:387-391.
95. Bishop AJ, Schiestl RH. Homologous recombination of mechanisms of carcinogenesis. Biochem Biophys Acta. 2001;1471:M109-M121.
96. Kolomietz E, Al-Maghrabi J, Brennan S, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletion and may lead to altered prognosis regions. Blood. 2001;97:3581-3588.
97. Huettner CS, Zhang P, van Etten RA, Tenen DG. Reversibility of acute B-cell leukemia induced by BCR/ABL-1. Nat Genet. 2000;24:57-60.
98. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
99. bcr/abl-transduced bone marrow. Blood. 1998;92:3780-3792.
100. Heisterkamp N, Jenster G, ten Hoeve J, Zovich P, Pattengale PK, Groffen J. Acute leukemia in Bcr/abl transgenic mice. Nature. 1990;344:251-253.
101. Voncken JW, Griffiths S, Greaves MF, Pattengale PK, Heisterkamp N, Grofffen J. Restricted oncogenicity of BCR/ABL p190 in transgenic mice. Cancer Res. 1992;52:4534-4539.
102. Honda H, Fugii T, Takatoku M, et al. Expression of p210bcr/abl by metallothionein promoter induces T-cell leukemia in transgenic mice. Blood. 1995;85:2853-2860.
103. Honda H, Oda H, Suzuki T, et al. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. Blood. 1998;91:2067-2075.
104. Huettner CS, Koschmieder S, Iwasaki H, et al. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood. 2003;102:3363-3370.
105. Corral J, Lavenin I, Impey H, et al. An MLL-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell. 1996;85:853-861.
106. Castellanos A, Pintado B, Wernaga E, et al. A BCR/ABL (p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. Blood. 1997;90:2168-2174.
107. Heisterkamp N, Jenster G, Kioussis D, Pattengale PK, Groffen J. Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Res. 1991;1:45-53.
108. Higuchi M, O'Brien D, Kumaravely P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63-74.
109. Forster A, Pannel R, Drynan LF, et al. Engineering de novo reciprocal chromosomal translocation associated with MLL to replicate primary events of human cancer. Cancer Cell. 2003;3:449-458.
110. Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ. A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1999;96:15103-15108.
111. Zimonjie DP, Pollock JL, Westervelt P, Popescu NC, Ley TJ. Acquired non-random chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A. 2000;97:13306-13311.
112. Huntly BJP, Bench A, Green A.R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 2003;102:1160-1168.
113. Salloukh HF, Laneuville P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia. 2000;14:1401-1404.
114. Brain JM, Goodyer N, Laneuville P. Measurement of genomic instability in preleukemic P190BCR/ABL transgenic mice using inter-simple sequence repeat polymerase chain reaction. Cancer Res. 2003;63:4895-4898.
115. Sill H, Chese A, Mills KI, et al. No evidence of microsatellite instability or coexistent loss of heterozygosity at selected loci in chronic myeloid leukemia blast crisis. Leukemia. 1994;8:1423-1428.
116. Mori N, Tekeuchi S, Tasaka T, et al. Absence of microsatellite instability during the progression of chronic myelocytic leukemia. Leukemia. 1997;11:151-152.
117. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76-94.
118. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci U S A. 1989;86:6783-6787.
119. Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci U S A. 1991;88:6293-6297.
120. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 1995;85:2013-2016.
121. Prigogina EL, Fleischman EW, Volkova MA, Frenkel MA. Chromosome abnormalities and cloned and morphologic manipulations of chronic myeloid leukemia. Hum Genet. 1978;41:143-156.
122. Blick M, Romero P, Talpaz M, et al, Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet. 1987;27:349-356.
123. Jennings BH, Mills KI. C-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukemia. Leuk Res. 1998;22:849-903.
124. Virtaneva K, Wright FA, Tanner SM, et al. Expression profiling reveals fundamental biologic differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A. 2001;98:1124-1129.
125. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901-910.
126. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood. 1996;88:1005-1012.
127. 1-positive or -negative myeloid leukemia. Leuk Res. 1993;17:533-539.
128. Fioretos T, Strombeck B, Sandberg T, et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood. 1999;94:225-232.
129. Zhang DE, Zhang P, Wong MD, Hetherington CJ, Darlington GJ, Tenen DJ. Absence of granulocyte colony-stimulating factor signaling and neutrophic development in CCAAT/enhancer binding protein alpha-different mice. Proc Natl Acad Sci U S A. 1997;94:569-574.
130. Perrotti P, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30:48-56.
131. Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell. 2003;3:145-160.
132. Tanaka T, Mitani K, Kurokawa M, et al. Dual functions of the AML1/EVi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Mol Cell Biol. 1995;15:2383-2392.
133. Ghannam G, Takeda A, Camarata T, Moore MA, Viale A, Yaseen NR. The oncogene Nup 98-HOXA9 induces gene transcription in myeloid cells. J Biol Chem. 2004;279:866-875.
134. Bames DJ, Goldman J, Melo JV. BCR/ABL expression levels determine the rate of development of resistance to Imatinib mesylate (Gleevec) [abstract]. Blood. 2003;101:415a.
135. Asimakopoulos FA, Shteper PJ, Krichevsky S, et al. Abl-1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood. 1999;94:2452-2460.
136. Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene. 2000;19:5643-5650.
137. Mitani K, Ogawa S, Tanaka T, et al. Generation of the AML 1-Evi-1 fusion gene in the t(3;21)(p26; p22) causes blast crisis in chronic myelocytic leukemia. EMBO J. 1994;13:504-510.
138. Nakamura T, Largaespeda DA, Lee MP, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15; p15) in human myeloid leukemia. Nat Genet. 1996;12:154-158.
139. Cuenco GM, Ren R. Cooperation of BCR-ABL and AML1/MD31/EVI1 in blocking myeloid differentiation and rapid induction of on acute myelogenous leukemia. Oncogene. 2001;20:8236-8248.
140. Kurokawa M, Mitani K, Irie K, et al. The oncoprotein Evi-1 represses TGF-ßene signalling by inhibitory Smad3. Nature. 1998;346:91-96.
141. Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. The t(3;21) fusion product, AML 1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. Blood. 1994;42:4003-4012.
142. Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. NUP98-HOX A9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 2001;20:350-361.
143. Dash A, Williams IR, Kutok J, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HoxA9. Proc Natl Acad Sci U S A. 2002;99:7622-7627.
144. Mayotte N, Roy DC, Yao J, Kroon E, Sauvageau G. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Blood. 2002;100:4177-4184.
145. Gilliland DG and Tallman MS. Focus on acute leukemias. Cancer Cell. 2002;1:417-420.
146. bcr/abl tyrosine kinase. Proc Natl Acad Sci U S A. 1996;99:13137-13142.
147. bcr/abl-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood. 2000;95:1144-1150.
148. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 1992;356:215-221.
149. Wlodarski P, Wasik MA, Ratajczak MZ, et al. Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood. 1998;91:2998-3006.
150. Serra A, Gottardi E, Della Ragione F, Saglio G, Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br J Haematol. 1995;91:625-629.
151. Hemández-Boluda JC, Cervantes F, Colomer D, et al. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. Exp Hematol. 2003;31:204-210.
152. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:27-37.
153. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression of the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91:649-659.
154. Kamijo T, Bodner S, van de Kamp E, Randle DH, Shen CJ. Tumor spectrum in ARF-deficient mice. Cancer Res. 1999;59:2217-2222.
155. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16 INK4a confers susceptibility to metastatic melanomas in mice. Nature. 2001;413:83-86.
156. Sharpless NE, Bardesy N, Lee KH, et al. Loss of p16 INK4a with retention of pl 9ARF predisposes mice to tumorigenesis. Nature. 2001;413:86-91.
157. Radfar A, Unnikrishnan I, Lee HW, DePinho RA, Rosenberg N. p19 (Arf) induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A. 1998;95:13194-13199.
158. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing hematopoietic stem cells. Nature. 2003;423:302-305.
159. Tao W, Levine, AJ. pl 9(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of MDM2. Proc Natl Acad Sci U S A. 1999;96:6937-6941.
160. Kuo ML, Duncavage EJ, Mathew R, et al. ARF induces p53-dependent and -independent antiproliferative genes. Cancer Res. 2003;63:1046-1053.
161. Ahuja HG, Jat PS, Foti A, Bar-Eli M, Cline MJ. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood. 1991;78:3259-3268.
162. Towatari M, Adachi K, Kato H, Salto H. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood. 1991;78:2178-2181.
163. Beck Z, Kiss A, Toth FD, et al. Alterations of p53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma. 2000;38:587-597.
164. LeMaistre A, Lee MS, Talpaz M, et al. Ras oncogene mutations are rare late-stage events in chronic myelogenous leukemia. Blood. 1989;73:889-891.
165. Watzinger R, Gaiger A, Karlie H, Becter R, Pillwein K, Lion T. Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia. Cancer Res. 1994;54:3934-3938.
166. Aggerholm A, Gronback K, Guldberg P, Hokland P. Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol. 2000;65:109-113.
167. Sirard C, Lapidot T, Vormoor J, et al. Normal and Leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood. 1996;87:1539-1548.
168. - leukemic cells from CML patients with chronic phase disease and then progressively decrease as they differentiate [abstract]. Blood. 2003;101:418a.
169. Hahn WC, Weinberg RA. Modeling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2:331-341.
170. Muller C, Alunni-Fabbroni M, Kowlenz-Leutz E, Mo X, Tommasino M, Leutz A. Separation of C/EBPα-mediated proliferation arrest and differentiation pathways. Proc Natl Acad Sci U S A. 1999;96:7276-7281.
171. Dierov J, Dierova R, Carroll M. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell. 2004;5:275-285.